While Exelixis Inc has underperformed by -4.42%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EXEL rose by 0.73%, with highs and lows ranging from $49.62 to $31.90, whereas the simple moving average jumped by 8.97% in the last 200 days.
On January 08, 2026, Morgan Stanley Downgraded Exelixis Inc (NASDAQ: EXEL) to Equal-Weight. A report published by BofA Securities on January 05, 2026, Downgraded its rating to ‘Underperform’ for EXEL. Leerink Partners October 21, 2025d its ‘Market Perform’ rating to ‘Outperform’ for EXEL, as published in its report on October 21, 2025. Barclays’s report from September 19, 2025 suggests a price prediction of $40 for EXEL shares, giving the stock a ‘Equal Weight’ rating. Barclays also rated the stock as ‘Equal Weight’.
Analysis of Exelixis Inc (EXEL)
Further, the quarter-over-quarter increase in sales is 10.79%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Exelixis Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of 30.56% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.68, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and EXEL is recording an average volume of 2.77M. On a monthly basis, the volatility of the stock is set at 3.00%, whereas on a weekly basis, it is put at 4.12%, with a gain of 0.73% over the past seven days. Furthermore, long-term investors anticipate a median target price of $45.33, showing growth from the present price of $44.15, which can serve as yet another indication of whether EXEL is worth investing in or should be passed over.
How Do You Analyze Exelixis Inc Shares?
Exelixis Inc (EXEL) is based in the USA and is one of the most prominent companies operating in the Biotechnology market. When comparing Exelixis Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 18.59, there is a growth in quarterly earnings of 71.73%.
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.17%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 94.52% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
